Awakn Partners With University Of Nottingham For Preclinical Testing Of Psychoactive Therapy
Awakn Partners With University Of Nottingham For Preclinical Testing Of Psychoactive Therapy
Awakn Life Sciences Corp. (OTC:AWKNF), a clinical-stage biotechnology company, has announced a new partnership with the University of Nottingham to conduct in vivo testing of its aminoindane new chemical entity as part of its preclinical program. This research will explore the therapeutic potential of Awakn's aminoindane, or psychoactive, series in enhancing social cognition and pro-social behaviors, particularly for trauma-related mental health disorders such as PTSD.
Awakn生命科学公司(OTC:AWKNF)，一家临床阶段生物技术公司，已宣布与诺丁汉大学建立新合作伙伴关系，进行体内测试其氨基茚新化合物，作为其临床前项目的一部分。此研究将探索Awakn的氨基茚，或致幻，系列在增强社交认知和亲社会行为方面的治疗潜力，特别是针对创伤相关的精神健康障碍，如创伤后应激障碍。
The study, led by Dr. Madeleine King, an expert in behavioral neuroscience, will utilize rodent models to evaluate the compound's efficacy through the Social Transmission of Food Preferences test. Results from the trial are expected by the end of 2024. This partnership follows Awakn's recent collaboration with Eurofins Discovery for in vitro pharmacology testing of the same aminoindane series, marking significant progress in Awakn's research and development pipeline.
由行为神经科学专家Madeleine King博士领导的研究将利用啮齿动物模型来评估该化合物通过社会传播食物偏好测试的疗效。预计该试验结果将在2024年底前出炉。这一合作是Awakn最近与Eurofins Discovery合作进行相同氨基茚系列体外药理学测试的延伸，标志着Awakn在研发管线方面取得了重大进展。
Anthony Tennyson, CEO of Awakn Life Sciences, emphasized the significance of the partnership: "We believe this novel aminoindane has the potential to revolutionize mental health treatment, offering a safer alternative for trauma-related disorders such as PTSD."
Awakn生命科学公司首席执行官Anthony Tennyson强调了这一合作的重要性：“我们相信这种新型氨基茚有潜力革新精神健康治疗，为创伤相关障碍如创伤后应激障碍提供更安全的替代方案。”
Cover image made with AI
封面图片由人工智能制作
译文内容由第三方软件翻译。
